HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Yoshihiro Suematsu Toshiya Ohtsuka Shinichi Takamoto Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suematsu, Y. Articles by Takamoto, S. Search for Related Content PubMed PubMed Citation Articles by Suematsu, Y. Articles by Takamoto, S. Related Collections Myocardial infarction Related Article

Ann Thorac Surg 2002;73:173-179
© 2002 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Long-term treatment with nipradilol, a nitric oxide–releasing ß-adrenergic blocker, enhances postischemic recovery and limits infarct size

^a Department of Cardiothoracic Surgery, University of Tokyo, Tokyo, Japan
^b Department of Thoracic Surgery, Osaka Medical College, Osaka, Japan

Accepted for publication August 15, 2001.

* Address reprint requests to Dr Suematsu, Department of Cardiothoracic Surgery, University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo, 113-8655, Japan
e-mail: suematsu{at}aurora.dti.ne.jp

Background. This study examines whether the chronic administration of nipradilol, a nitric oxide–releasing ß-adrenergic blocker, decreases ischemia-reperfusion injury.

Methods. Rats were treated with nipradilol (10 mg/kg per day orally) or a vehicle alone for 4 weeks. Isolated rat hearts were assigned to one of five groups (each n = 6): global ischemia groups treated with the vehicle or with nipradilol were subjected to 20 minutes of ischemia; ischemic preconditioning groups treated with the vehicle or with nipradilol were subjected to 3 minutes of ischemic preconditioning; and the L-arginine group treated with the vehicle received 1 mmol/L of L-arginine before global ischemia. Hemodynamic variables and coronary flow were recorded continuously. Nitrites and nitrates levels were measured 60 minutes after reperfusion, and the infarct size was determined. In another series (each n = 6), lipid peroxidation was investigated.

Results. In the nipradilol group, significant preservation of the left ventricular pressure and coronary flow, as well as the level of nitrates and nitrites, was observed, compared with the global ischemia group. The infarct size was also significantly reduced in the ischemic preconditioning (23.5% ± 5.47%), L-arginine (25.6% ± 5.59%), and especially the nipradilol (10.7% ± 1.65%) groups. However, in the nipradilol plus ischemic preconditioning group, the protective effects were eliminated. Lipid peroxidation after nipradilol treatment was significantly reduced before and after global ischemia, compared with the global ischemia group.

Conclusions. The chronic administration of nipradilol improves postischemic functional recovery and infarct size, partly by preventing the formation of lipid peroxides. These cardioprotective effects were, however, abolished by ischemic preconditioning.

Related Article

Invited commentary

Ann. Thorac. Surg. 73: 179-179. [Full Text]

This article has been cited by other articles:

				S. Mieno, H. Horimoto, K. Kishida, S. Horimoto, and S. Sasaki Landiolol Enhances Effect of Ischemic Preconditioning in Isolated Rabbit Hearts Asian Cardiovasc Thorac Ann, June 1, 2006; 14(3): 239 - 243. [Abstract] [Full Text] [PDF]

				B. Bartling, I. Friedrich, R.-E. Silber, and A. Simm Ischemic preconditioning is not cardioprotective in senescent human myocardium Ann. Thorac. Surg., July 1, 2003; 76(1): 105 - 111. [Abstract] [Full Text] [PDF]

				P. L. Hooper Diabetes, Nitric Oxide, and Heat Shock Proteins Diabetes Care, March 1, 2003; 26(3): 951 - 952. [Full Text] [PDF]